Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study.
Cano-Jiménez E, Villar Gómez A, Velez Segovia E, Aburto Barrenechea M, Sellarés Torres J, Francesqui J, Portillo Carroz K, Solis Solis AJ, Acosta Fernández O, Llanos González AB, Bordas-Martinez J, Cabrera Cesar E, Balcells Vilarnau E, Castillo Villegas D, Reyes Pardessus A, González Fernández C, García Moyano M, Urrutia Gajate A, Blanco Hortas A, Molina-Molina M. Cano-Jiménez E, et al. Among authors: castillo villegas d. ERJ Open Res. 2024 Feb 26;10(1):00405-2023. doi: 10.1183/23120541.00405-2023. eCollection 2024 Jan. ERJ Open Res. 2024. PMID: 38410707 Free PMC article.
Predictors and changes of physical activity in idiopathic pulmonary fibrosis.
Badenes-Bonet D, Rodó-Pin A, Castillo-Villegas D, Vicens-Zygmunt V, Bermudo G, Hernández-González F, Portillo K, Martínez-Llorens J, Chalela R, Caguana O, Sellarés J, Molina-Molina M, Duran X, Gea J, Rodríguez-Chiaradia DA, Balcells E. Badenes-Bonet D, et al. Among authors: castillo villegas d. BMC Pulm Med. 2022 Sep 9;22(1):340. doi: 10.1186/s12890-022-02134-4. BMC Pulm Med. 2022. PMID: 36085057 Free PMC article.
Biological Biomarkers in Respiratory Diseases.
García-Río F, Alcázar-Navarrete B, Castillo-Villegas D, Cilloniz C, García-Ortega A, Leiro-Fernández V, Lojo-Rodriguez I, Padilla-Galo A, Quezada-Loaiza CA, Rodriguez-Portal JA, Sánchez-de-la-Torre M, Sibila O, Martínez-García MA. García-Río F, et al. Among authors: castillo villegas d. Arch Bronconeumol. 2022 Apr;58(4):323-333. doi: 10.1016/j.arbres.2022.01.003. Epub 2022 Jan 17. Arch Bronconeumol. 2022. PMID: 35312522 Free article. Review. English, Spanish.
Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association.
Sebastiani M, Luppi F, Sambataro G, Castillo Villegas D, Cerri S, Tomietto P, Cassone G, Bocchino M, Atienza-Mateo B, Cameli P, Moya Alvarado P, Faverio P, Bargagli E, Vancheri C, Gonzalez-Gay MA, Clini E, Salvarani C, Manfredi A. Sebastiani M, et al. Among authors: castillo villegas d. J Clin Med. 2021 Jun 9;10(12):2548. doi: 10.3390/jcm10122548. J Clin Med. 2021. PMID: 34207641 Free PMC article.
Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis.
Cano-Jiménez E, Vázquez Rodríguez T, Martín-Robles I, Castillo Villegas D, Juan García J, Bollo de Miguel E, Robles-Pérez A, Ferrer Galván M, Mouronte Roibas C, Herrera Lara S, Bermudo G, García Moyano M, Rodríguez Portal JA, Sellarés Torres J, Narváez J, Molina-Molina M. Cano-Jiménez E, et al. Among authors: castillo villegas d. Sci Rep. 2021 Apr 28;11(1):9184. doi: 10.1038/s41598-021-88734-2. Sci Rep. 2021. PMID: 33911185 Free PMC article.
Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey.
Funke-Chambour M, Albera C, Bendstrup E, Costabel U, Grutters JC, Harari S, Johannson KA, Kreuter M, Strambu I, Vancheri C, Varone F, Vitulo P, Wuyts WA, Martinez F, Raghu G; Erice participants; Erice participants:. Funke-Chambour M, et al. Eur Respir J. 2021 Apr 29;57(4):2004219. doi: 10.1183/13993003.04219-2020. Print 2021 Apr. Eur Respir J. 2021. PMID: 33419886 Free article. No abstract available.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
20 results